Kee-Hong Kim
About Kee-Hong Kim
Chief Technology Officer at Tenaya Therapeutics
Kee-Hong Kim holds the position of Chief Technology Officer at Tenaya Therapeutics. He joined the company in 2018, bringing with him extensive experience in biopharma, particularly in gene therapy and process development. His role at Tenaya Therapeutics involves overseeing the company's technological strategies and initiatives, aiming to advance the therapeutic development programs.
Previous Roles at Agilis Biotherapeutics and Shire
Before joining Tenaya Therapeutics, Kee-Hong Kim served as the Senior Vice President and Head of Technical Operations at Agilis Biotherapeutics. Additionally, he held a significant role at Shire as the Head of Gene Therapy Process Development and the Global CMC Lead for Gene Therapy. These positions enabled him to develop expertise in technical operations and process development in the biopharma sector.
Career in Biopharma Consulting and Process Development
Kee-Hong Kim ran his own biopharma consulting firm, providing his expertise to various organizations. He also worked at Avalanche Biotechnology (now Adverum) as Director of Process Development. In this role, he contributed to the development of manufacturing processes and regulatory filings. His career reflects significant contributions to the field of process development and biopharma consulting.
Educational Background and Post-Doctoral Training
Kee-Hong Kim's academic journey includes a doctoral degree in chemical engineering from Colorado State University. Following his Ph.D., he completed post-doctoral training at Cornell University. This strong foundation in chemical engineering and advanced training has equipped him with the skills necessary for his roles in biopharma and gene therapy.
Experience at Technical Organizations
Over his career, Kee-Hong Kim has held roles of increasing responsibility at several technical organizations, including the Aeras TB Foundation and the Walter Reed Army Medical Center. His work at these institutions involved various aspects of process development and manufacturing science, further solidifying his expertise in the biopharma industry.